NCT06398977 Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients
| NCT ID | NCT06398977 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sichuan Academy of Medical Sciences |
| Condition | Peritoneal Dialysis Complication |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2024-03-11 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2024-03-11 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.
Eligibility Criteria
Inclusion Criteria: * Patients with PD duration between 1 month and 3 months. * Patients aged between 18 and 75 years. * Voluntary signing of informed consent. * Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present. * Daily urine output ≥ 400ml/day. * Stable PD prescription for one month. Exclusion Criteria: * Pregnant and lactating women. * Patients with type 1 diabetes mellitus. * Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past. * Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \> 120 IU/L, and other clinically confirmed severe liver diseases. * Patients with more than 2 episodes of urinary tract infection in the past six months. * Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin. * Patients using the following medications: rifampicin, phenytoin. * Patients with malignant tumors. * Patients who developed peritonitis within one month. * Patients undergoing combined hemodialysis treatment. * Patients with a willingness for kidney transplantation within six months. * Patients with a history of pancreatitis or pancreatic transplantation. * Patients who experienced acute coronary syndrome or cerebrovascular events within one month. * Hemoglobin level less than 90g/L.
Contact & Investigator
Jin Chen, MD
PRINCIPAL INVESTIGATOR
Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
Frequently Asked Questions
Who can join the NCT06398977 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Peritoneal Dialysis Complication. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06398977 currently recruiting?
Yes, NCT06398977 is actively recruiting participants. Contact the research team at jessicakxcj@uestc.edu.cn for enrollment information.
Where is the NCT06398977 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT06398977 clinical trial?
NCT06398977 is sponsored by Sichuan Academy of Medical Sciences. The principal investigator is Jin Chen, MD at Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital. The trial plans to enroll 70 participants.